1999
DOI: 10.1097/00005392-199904010-00620
|View full text |Cite
|
Sign up to set email alerts
|

Randomized Comparative Study of 3 vs 8 Months of Neoadjuvant Hormonal Therapy Prior to Radical Prostatectomy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2000
2000
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 0 publications
0
13
0
Order By: Relevance
“…CUOG-P95A randomized 547 men with clinically con®ned prostate cancer to either 3 or 8 months of leuprolide acetate and¯utamide prior to radical prostatectomy. 47 The study was powered to detect a 25% decrease in PSA recurrence, assuming a 30% recurrence in the 3 month arm after 3 y. Patients were equally strati®ed for clinical stage, Gleason grade and serum PSA.…”
Section: Clinical Studies With Long-term Neoadjuvant Therapymentioning
confidence: 99%
“…CUOG-P95A randomized 547 men with clinically con®ned prostate cancer to either 3 or 8 months of leuprolide acetate and¯utamide prior to radical prostatectomy. 47 The study was powered to detect a 25% decrease in PSA recurrence, assuming a 30% recurrence in the 3 month arm after 3 y. Patients were equally strati®ed for clinical stage, Gleason grade and serum PSA.…”
Section: Clinical Studies With Long-term Neoadjuvant Therapymentioning
confidence: 99%
“…Gleave et al [ 37 ] addressed the question of duration of NADT by randomly allocating 549 men to receive 3 versus 8 months of therapy. Again, margin-positive rates declined from 23% to 12% (P = 0.01), but no difference in biochemical-free survival at 3 years was observed between the two groups [ 38 ]. Although the study by Klotz et al [ 34 ] provides preliminary evidence suggesting that high-risk patients may benefi t from a short course of NADT before RP, its small size (17 high-risk patients in each arm) and the relatively high failure rate among patients assigned to the control arm preclude uniform adoption of its fi ndings.…”
Section: Multimodality Approachmentioning
confidence: 87%
“…Positive margin rates were significantly lower in the 8-month than the 3-month group (12% vs 23%; P = 0.0106). However, in a recent update [42], biochemical failure rates were similar in both groups at median followup of 37.7 months. Bono et al [37] found improved pathological staging with 6 rather than 3 months of neoadjuvant treatment with goserelin plus bicalutamide, but longer outcomes have not been reported.…”
Section: Neoadjuvant/adjuvant Hormonal Therapy With Radical Prostatecmentioning
confidence: 89%